Lilly's New Weight-Loss Combo Just Smashed Every Record on the Scale
Eli Lilly's new two-drug obesity combo produced an average of 54 pounds of weight loss in 48 weeks, blowing past Zepbound alone. But a steep dropout rate from side effects means the real battle is just getting started.
Fifty-Four Pounds in Less Than a Year
Imagine stepping on a scale and seeing a number 54 pounds lighter than where you started. Not after surgery. Not after a year of boot camp. After 48 weeks of a two-drug injection combo that Eli Lilly just tested in a mid-stage obesity trial.
That's the headline number from Lilly's Phase 2b study of eloraTZP, a combination of eloralintide (a new amylin-targeting drug) and tirzepatide (the active ingredient in Zepbound, the blockbuster weight-loss injection you've probably seen advertised everywhere). The highest-dose group lost an average of 23.3% of their body weight, translating to roughly 54.1 pounds across 48 weeks.
For context, patients on Zepbound alone in the same trial lost about 14.8%, or 34.4 pounds. The combo didn't just win; it lapped the field.
Two Hormones Are Better Than One
So why does adding a second drug make such a big difference? Think of it like a stereo system with two speakers instead of one. Each speaker handles a different frequency range, and together they produce sound that neither could achieve alone.
Zepbound works by mimicking two gut hormones called GLP-1 and GIP. These are the incretin signals that tell your brain you're full after a meal, slow digestion, and improve blood sugar control. Zepbound is already one of the most effective obesity drugs ever approved. But it only covers part of the appetite orchestra.
Eloralintide targets a completely different hormone: amylin. Your pancreas releases amylin alongside insulin after you eat. It promotes satiety (the feeling of "okay, I'm done eating"), shrinks meal size, and slows how fast food leaves your stomach. By pairing an amylin agonist with a GIP/GLP-1 agonist, Lilly is essentially hitting the appetite control center from two different angles at once.
The study enrolled 367 adults with obesity or overweight who also had type 2 diabetes, a population that historically finds it harder to lose weight with medications alone. The combination met both its primary and secondary endpoints, and the highest dose (9 mg eloralintide plus 15 mg tirzepatide, both given weekly) also lowered on average. That's a remarkable blood sugar improvement stacked on top of the weight loss.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A1C by up to 2.9 percentage points
The Catch Nobody Wants to Talk About
Before you start planning the ticker-tape parade, there's a speed bump. A significant one.
The dropout rate in the combination arms was noticeably higher than in the Zepbound-alone group. Depending on the dose, between 10.8% and 27% of patients in the combo groups stopped treatment because of side effects, mostly gastrointestinal issues like nausea. That's the kind of range that makes doctors pause and investors squint.
This is the classic pharma tradeoff: more efficacy, more side effects. If one in four patients at the highest dose can't tolerate the treatment, the real-world weight loss numbers will look different from the clinical trial headlines. The patients who stayed on the drug lost a stunning amount of weight. The question is how many patients can stay on the drug.
Wall Street noticed. Analysts acknowledged the impressive efficacy but zeroed in on tolerability as the key variable that will determine whether this combination becomes a commercial juggernaut or a niche option for patients who can handle the side effects.
The Obesity Arms Race Just Got a New Weapon
Lilly isn't the only company betting on amylin. Novo Nordisk, Lilly's main rival in the obesity wars, has its own amylin combination called CagriSema (cagrilintide plus semaglutide), which is further along in regulatory development. Novo is also working on zenagamtide, a single molecule that combines GLP-1 and amylin activity in one shot.
The broader competitive picture looks like a chess match with multiple boards. Lilly's advantage is the strength of its tirzepatide backbone: Zepbound is already a proven powerhouse, and layering amylin on top could extend its lead. Novo's advantage is breadth, with both a fixed-dose combination and a single-molecule approach covering different strategic angles.
Meanwhile, Amgen is pushing mariTide, a long-acting incretin-based candidate, and Viking Therapeutics has obesity assets that could matter down the road, including its lead candidate VK2735 in Phase 3 and earlier-stage programs behind it. But for the moment, the Lilly vs. Novo rivalry is the main event.
The industry takeaway is clear: amylin is emerging as the next frontier in obesity pharmacotherapy. The first generation of this war was about GLP-1 drugs. The second generation was about dual agonists like Zepbound. The third generation will likely be about multi-hormone combinations, and amylin looks like the ingredient everyone wants to add to the recipe.
Lilly's Bigger Playbook
What makes Lilly's strategy interesting is that eloraTZP isn't a standalone bet. It's one piece of a much larger obesity portfolio the company is assembling.
Orforglipron (Foundayo) is Lilly's oral GLP-1 candidate, a once-daily pill designed for patients who don't want injections. It could expand the addressable market dramatically, since many people who would benefit from obesity drugs simply won't use a needle. Orforglipron received FDA approval in April 2026 and has already launched in the U.S.
Then there's retatrutide, a triple agonist that targets GLP-1, GIP, and glucagon. In trials, it has shown weight loss exceeding current approved therapies, and Lilly is expected to file for approval in early 2027.
Add eloralintide and the amylin combination strategy on top, and you get a company that's building an obesity franchise the way a smart investor builds a portfolio: diversified across mechanisms, delivery methods, and patient types. Pills for the needle-averse. Triple agonists for maximum efficacy. Amylin combos for the next wave of treatment intensification.
What Comes Next
Lilly plans to move eloraTZP into Phase 3 trials based on these results. That's the final, large-scale testing stage before a company can apply for FDA approval. If the combination can demonstrate similar efficacy in a bigger, longer study while keeping the dropout rate manageable, it could redefine what "good enough" weight loss looks like for obesity drugs.
The bar in this space keeps rising. A few years ago, losing 15% of body weight on a medication was considered remarkable. Zepbound pushed that toward 20%. Now Lilly is showing that 23% or more might be achievable with the right combination.
For patients, this is genuinely exciting. For Lilly's competitors, it's a fire alarm. And for anyone watching the obesity drug market, the message is simple: the incretin era isn't ending, but it's about to get a very powerful co-pilot.
4 min read
The Pill That Could Replace the Needle in Breast Cancer Treatment
Genentech's oral pill giredestrant just posted Phase 3 results in the NEJM that could shake up breast cancer treatment. In patients whose cancers outsmarted standard therapy, it cut the risk of progression by up to 62%, and Roche already has an FDA application under review.
